Business
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company
About this update from Gain Therapeutics, Inc.
[{"type":"text","content":"BETHESDA, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the formation of its Clinical Advisory Board (CAB) to support the continued development of the Company’s lead drug candidate, GT-02287, in Parkinson’s disease. The CAB is composed of leading experts in Parkinson’s disease trial design, genetics, and biomarkers and will work closely with Gain leadership to progress GT-02287 through potential Phase 2 and Phase 3 clinical development. “The formation of Gain’s new Clinical Advisory Board marks a significant strategic step forward for Gain, as GT-02287 advances into Parkinson’s disease patients,” stated Gene Mack, CEO of Gain Therapeutics. “We are confident that the collective expertise of this Clinical Advisory Board will be invaluable as we strive to deliver a meaningful new treatment option for Parkinson's disease patients.” Gain Scientific Advisory Board Members Karl Kieburtz, M.D., M.P.H. is a Professor of Neurology (part time) at the University of Rochester, was the founding Director of the Center of Health & Technology (CHET), and served as the Director of the Clinical and Translational Science Institute and Senior Associate Dean for Clinical Research at the University of Rochester. Dr. Kieburtz also served as the Chair of the Parkinson Study Group Executive Committee and chaired the FDA’s Peripheral and Central Nervous System Advisory Committee. He has been global Principal Investigator for more than 50 multi-center and multi-national NIH, industry, and Foundation sponsored clinical trials, including the large NIH-sponsored NET-PD study. He was elected as a Fellow in the American Association for the Advancement of Sciences in 2014. In 2008, he co-founded Clintrex Research Corporation, now a part of Tox Strategies, which provides scientific and regulatory advisory services to companies developing CNS therapies. Roy Alcalay, M.D., M.S. is Chief of the Movement Disorders Division at Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. He moved from Columbia University where he holds a part-time associate professorship. He obtained his medical degree from Tel Aviv University, his neurology training from the Harv...